PLX— Protalix BioTherapeutics, Inc.

MaterialsBiotechnology$198M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
TOTAL REVENUE	$52.7M-1.2%	$53.4M-18.5%	$65.5M+37.5%	$47.6M
COST OF GOODS SOLD	-$27.0M-11.0%	-$24.3M-5.8%	-$23.0M-17.3%	-$19.6M
RESEARCH AND DEVELOPMENT EXPENSES	-$19.6M-50.9%	-$13.0M+24.1%	-$17.1M+41.8%	-$29.3M
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	-$11.7M+4.2%	-$12.2M+18.5%	-$15.0M-27.7%	-$11.7M
OPERATING INCOME (LOSS)	-$5.5M-240.4%	$3.9M-62.6%	$10.5M+180.4%	-$13.0M
FINANCIAL EXPENSES	-$1.2M-12.1%	-$1.1M+66.6%	-$3.2M-25.7%	-$2.5M
FINANCIAL INCOME	$1.1M-16.6%	$1.3M+1.0%	$1.3M+12.2%	$1.1M
FINANCIAL INCOME (EXPENSES), NET	-$108K-145.6%	$237K+112.5%	-$1.9M-36.9%	-$1.4M
INCOME (LOSS) BEFORE TAXES ON INCOME	-$5.6M-235.0%	$4.2M-51.5%	$8.6M+159.5%	-$14.4M
TAXES ON INCOME	-$996K+18.5%	-$1.2M-381.1%	-$254K+52.1%	-$530K
NET INCOME (LOSS)	-$6.6M-325.2%	$2.9M-64.7%	$8.3M+155.7%	-$14.9M
EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC (in dollars per share)	-$80.00-300.0%	$40.00-66.7%	$120.00+138.7%	-$310.00
EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)	-$80.00-300.0%	$40.00-55.6%	$90.00+129.0%	-$310.00
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC (in shares)	$78546234000.00+8.3%	$72530698000.00+7.4%	$67512527000.00+39.3%	$48472159000.00
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - DILUTED (in shares)	$78546234000.00-3.1%	$81057176000.00-1.7%	$82424016000.00+70.0%	$48472159000.00
Goods
License and R&D Services

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.